Monday, November 26, 2018 4:56:02 PM
They have also announced that there will be an additional two INDs filed by the end of the year. Dr.Wijatyk spoke about the second generation CTLA-4 IND and the two new INDs as follows...
"Today, I am pleased to announce that we have filed an IND for our next generation CTLA-4 antibody. We have briefly described our next-generation CTLA-4, AGEN1181, in our last earnings call. This molecule, we believe, will have both potential efficacy and safety advantages relative to competitor molecules, including: one, enhanced potency through increased potential for T cell priming, while we also achieve Treg depletion. This is a very challenging and unique attribute that we have been able to achieve with this molecule; two, broader benefit to a wider patient population, including the approximately 40% of patients who are unlikely to respond to first-generation CTLA-4 therapies due to a genetic predisposition; and third, improved safety through Fc engineering to avoid common side effects of first-generation CTLA-4 antibody and enhanced therapeutic potential to enable broader range of dosing options, all of which have been achieved with 1181 based on the data that we have generated in preclinical models so far.
As I said earlier, additionally, we are on track to file INDs for 2 of our first-in-class bispecific antibodies this year."
These are very important best-in-class and first-in-class drugs!
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent AGEN News
- The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline • PR Newswire (US) • 09/23/2024 09:45:00 AM
- Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN) • PR Newswire (US) • 09/19/2024 09:45:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 • Business Wire • 09/13/2024 02:00:00 PM
- Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/11/2024 06:25:00 PM
- Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 • Business Wire • 09/09/2024 11:30:00 AM
- Agenus to Participate in September Investor Conferences • Business Wire • 09/03/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:49:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:47:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:08:46 PM
- Agenus Reports Second Quarter 2024 Operational and Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Announces Appointment of Tom Harrison to Board of Directors • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers • Business Wire • 08/07/2024 02:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:02:09 PM
- Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update • Business Wire • 07/26/2024 11:00:00 AM
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM